Protection of IFNAR (-/-) Mice against Bluetongue Virus Serotype 8, by Heterologous (DNA/rMVA) and Homologous (rMVA/rMVA) Vaccination, Expressing Outer-Capsid Protein VP2

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Jabbar, Tamara Kusay ^a   Calvo Pinilla, Eva ^a   Mateos, Francisco ^b   Gubbins, Simon ^a   Bin Tarif, Abdelghani ^a   Bachanek Bankowska, Katarzyna ^a   Alpar, Oya ^c   Ortego, Javier ^b   Takamatsu, Haru Hisa ^a   Mertens, Peter Paul Clement ^a   Castillo Olivares, Javier ^a  

^a INSTITUTE FOR ANIMAL HEALTH   (United Kingdom)

^b Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria   (Spain)

^c UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; MODIFIED VACCINIA ANKARA VIRUS VACCINE; NEUTRALIZING ANTIBODY; PLASMID DNA; PROTEIN VP2; PROTEIN VP5; PROTEIN VP7; UNCLASSIFIED DRUG; VIRUS RNA; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; BLUETONGUE; CONTROLLED STUDY; DRUG EFFICACY; IMMUNE RESPONSE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SEROLOGY; SURVIVAL RATE; VIREMIA; VIRUS DETECTION; VIRUS IMMUNITY;

ANIMALS; ANTIBODIES, NEUTRALIZING; BLUETONGUE; BLUETONGUE VIRUS; CAPSID PROTEINS; CERCOPITHECUS AETHIOPS; CHICKENS; MICE; PLASMIDS; RECEPTOR, INTERFERON ALPHA-BETA; RNA, VIRAL; VACCINATION; VACCINES, DNA; VACCINES, SYNTHETIC; VERO CELLS; VIREMIA;

ANIMALIA; BLUETONGUE VIRUS; BLUETONGUE VIRUS 8; MIRIDAE; MUS;

EID: 84876083769     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060574     Document Type: Article

References (64)

1. Erasmus BJ, (1975) Bluetongue in sheep and goats. Aust Vet J 51: 165-170.
2. Darpel KE, Batten CA, Veronesi E, Shaw AE, Anthony S, et al. (2007) Clinical signs and pathology shown by British sheep and cattle infected with bluetongue virus serotype 8 derived from the 2006 outbreak in northern Europe. Vet Rec 161: 253-261.
3. Mertens PP, Brown F, Sangar DV, (1984) Assignment of the genome segments of bluetongue virus type 1 to the proteins which they encode. Virology 135: 207-217.
4. Belhouchet M, Mohd Jaafar F, Firth AE, Grimes JM, Mertens PP, et al. (2011) Detection of a fourth orbivirus non-structural protein. PLoS One 6: e25697.
5. Roy P, (1992) From genes to complex structures of bluetongue virus and their efficacy as vaccines. Vet Microbiol 33: 155-168.
6. Roy P, (1992) Bluetongue virus proteins. J Gen Virol 73 (Pt 12): 3051-3064.
7. Grimes JM, Burroughs JN, Gouet P, Diprose JM, Malby R, et al. (1998) The atomic structure of the bluetongue virus core. Nature 395: 470-478.
8. Bonneau KR, Mullens BA, MacLachlan NJ, (2001) Occurrence of genetic drift and founder effect during quasispecies evolution of the VP2 and NS3/NS3A genes of bluetongue virus upon passage between sheep, cattle, and Culicoides sonorensis. J Virol 75: 8298-8305.
9. Anthony S, Jones H, Darpel KE, Elliott H, Maan S, et al. (2007) A duplex RT-PCR assay for detection of genome segment 7 (VP7 gene) from 24 BTV serotypes. J Virol Methods 141: 188-197.
10. Maan S, Maan NS, Samuel AR, Rao S, Attoui H, et al. (2007) Analysis and phylogenetic comparisons of full-length VP2 genes of the 24 bluetongue virus serotypes. J Gen Virol 88: 621-630.
11. Maan S, Maan NS, Ross-smith N, Batten CA, Shaw AE, et al. (2008) Sequence analysis of bluetongue virus serotype 8 from the Netherlands 2006 and comparison to other European strains. Virology 377: 308-318.
12. Maan S, Maan NS, Nomikou K, Veronesi E, Bachanek-Bankowska K, et al. (2011) Complete genome characterisation of a novel 26th bluetongue virus serotype from Kuwait. PLoS One 6: e26147.
13. Huismans H, van der Walt NT, Cloete M, Erasmus BJ, (1987) Isolation of a capsid protein of bluetongue virus that induces a protective immune response in sheep. Virology 157: 172-179.
14. DeMaula CD, Bonneau KR, MacLachlan NJ, (2000) Changes in the outer capsid proteins of bluetongue virus serotype ten that abrogate neutralization by monoclonal antibodies. Virus Res 67: 59-66.
15. Mertens PP, Pedley S, Cowley J, Burroughs JN, Corteyn AH, et al. (1989) Analysis of the roles of bluetongue virus outer capsid proteins VP2 and VP5 in determination of virus serotype. Virology 170: 561-565.
16. Cowley JA, Gorman BM, (1987) Genetic reassortants for identification of the genome segment coding for the bluetongue virus hemagglutinin. J Virol 61: 2304-2306.
17. Hutchinson I (1999) The role of VP7 in initiation of infection by bluetongue virus. United Kingdom: University of Hertfordshire.
18. Mertens PP, Burroughs JN, Walton A, Wellby MP, Fu H, et al. (1996) Enhanced infectivity of modified bluetongue virus particles for two insect cell lines and for two Culicoides vector species. Virology 217: 582-593.
19. Mertens PP, Maan NS, Prasad G, Samuel AR, Shaw AE, et al. (2007) Design of primers and use of RT-PCR assays for typing European bluetongue virus isolates: differentiation of field and vaccine strains. J Gen Virol 88: 2811-2823.
20. Hofmann M, Griot C, Chaignat V, Perler L, Thur B, (2008) Bluetongue disease reaches Switzerland. Schweiz Arch Tierheilkd 150: 49-56.
21. Saegerman C, Mellor P, Uyttenhoef A, Hanon JB, Kirschvink N, et al. (2010) The most likely time and place of introduction of BTV8 into Belgian ruminants. PLoS One 5: e9405.
22. Gloster J, Burgin L, Witham C, Athanassiadou M, Mellor PS, (2008) Bluetongue in the United Kingdom and northern Europe in 2007 and key issues for 2008. Vet Rec 162: 298-302.
23. Gethmann J, Huttner K, Heyne H, Probst C, Ziller M, et al. (2009) Comparative safety study of three inactivated BTV-8 vaccines in sheep and cattle under field conditions. Vaccine 27: 4118-4126.
24. Veronesi E, Darpel KE, Hamblin C, Carpenter S, Takamatsu HH, et al. (2010) Viraemia and clinical disease in Dorset Poll sheep following vaccination with live attenuated bluetongue virus vaccines serotypes 16 and 4. Vaccine 28: 1397-1403.
25. Shaw AE, Monaghan P, Alpar HO, Anthony S, Darpel KE, et al. (2007) Development and initial evaluation of a real-time RT-PCR assay to detect bluetongue virus genome segment 1. J Virol Methods 145: 115-126.
26. Elia G, Savini G, Decaro N, Martella V, Teodori L, et al. (2008) Use of real-time RT-PCR as a rapid molecular approach for differentiation of field and vaccine strains of bluetongue virus serotypes 2 and 9. Mol Cell Probes 22: 38-46.
27. Boone JD, Balasuriya UB, Karaca K, Audonnet JC, Yao J, et al. (2007) Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep. Vaccine 25: 672-678.
28. Calvo-Pinilla E, Rodriguez-Calvo T, Sevilla N, Ortego J, (2009) Heterologous prime boost vaccination with DNA and recombinant modified vaccinia virus Ankara protects IFNAR(-/-) mice against lethal bluetongue infection. Vaccine 28: 437-445.
29. Savini G, MacLachlan NJ, Sanchez-Vizcaino JM, Zientara S, (2008) Vaccines against bluetongue in Europe. Comp Immunol Microbiol Infect Dis 31: 101-120.
30. Mayr A, Stickl H, Muller HK, Danner K, Singer H, (1978) The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl). Zentralbl Bakteriol B 167: 375-390.
31. Esteban M, (2009) Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS. Hum Vaccin 5: 867-871.
32. Ramirez JC, Gherardi MM, Esteban M, (2000) Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J Virol 74: 923-933.
33. Kennedy JS, Greenberg RN, (2009) IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine. Expert Rev Vaccines 8: 13-24.
34. Huismans H, (1985) The use of recombinant DNA technology for the development of a bluetongue virus subunit vaccine. Onderstepoort J Vet Res 52: 149-151.
35. Romito M, Du Plessis DH, Viljoen GJ, (1999) Immune responses in a horse inoculated with the VP2 gene of African horsesickness virus. Onderstepoort J Vet Res 66: 139-144.
36. MacLachlan NJ, Balasuriya UB, Davis NL, Collier M, Johnston RE, et al. (2007) Experiences with new generation vaccines against equine viral arteritis, West Nile disease and African horse sickness. Vaccine 25: 5577-5582.
37. Calvo-Pinilla E, Navasa N, Anguita J, Ortego J, (2012) Multiserotype protection elicited by a combinatorial prime-boost vaccination strategy against bluetongue virus. PLoS One 7: e34735.
38. Roy P, (1990) Use of baculovirus expression vectors: development of diagnostic reagents, vaccines and morphological counterparts of bluetongue virus. FEMS Microbiol Immunol 2: 223-234.
39. Scanlen M, Paweska JT, Verschoor JA, van Dijk AA, (2002) The protective efficacy of a recombinant VP2-based African horsesickness subunit vaccine candidate is determined by adjuvant. Vaccine 20: 1079-1088.
40. Stone-Marschat MA, Moss SR, Burrage TG, Barber ML, Roy P, et al. (1996) Immunization with VP2 is sufficient for protection against lethal challenge with African horsesickness virus Type 4. Virology 220: 219-222.
41. Castillo-Olivares J, Calvo-Pinilla E, Casanova I, Bachanek-Bankowska K, Chiam R, et al. (2011) A modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR -/- mouse model. PLoS One 6: e16503.
42. Calvo-Pinilla E, Rodriguez-Calvo T, Anguita J, Sevilla N, Ortego J, (2009) Establishment of a bluetongue virus infection model in mice that are deficient in the alpha/beta interferon receptor. PLoS One 4: e5171.
43. Paradell H, Garcia L, Urniza A, Vila A, San Miguel E, et al. (2008) Efficacy of ZULVAC® inactivated and adjuvanted vaccine against bluetongue virus Bluetongue minisymposium (Brescia).
44. Fiette L, Aubert C, Muller U, Huang S, Aguet M, et al. (1995) Theiler's virus infection of 129Sv mice that lack the interferon alpha/beta or interferon gamma receptors. J Exp Med 181: 2069-2076.
45. Ohka S, Igarashi H, Nagata N, Sakai M, Koike S, et al. (2007) Establishment of a poliovirus oral infection system in human poliovirus receptor-expressing transgenic mice that are deficient in alpha/beta interferon receptor. J Virol 81: 7902-7912.
46. Waibler Z, Anzaghe M, Ludwig H, Akira S, Weiss S, et al. (2007) Modified vaccinia virus Ankara induces Toll-like receptor-independent type I interferon responses. J Virol 81: 12102-12110.
47. Ma G, Eschbaumer M, Said A, Hoffmann B, Beer M, et al. (2012) An equine herpesvirus type 1 (EHV-1) expressing VP2 and VP5 of serotype 8 bluetongue virus (BTV-8) induces protection in a murine infection model. PLoS One 7: e34425.
48. Golde WT, Gollobin P, Rodriguez LL, (2005) A rapid, simple, and humane method for submandibular bleeding of mice using a lancet. Lab Anim (NY) 34: 39-43.
49. Franceschi V, Capocefalo A, Calvo-Pinilla E, Redaelli M, Mucignat-Caretta C, et al. (2011) Immunization of knock-out alpha/beta interferon receptor mice against lethal bluetongue infection with a BoHV-4-based vector expressing BTV-8 VP2 antigen. Vaccine 29: 3074-3082.
50. Wang Z, Martinez J, Zhou W, La Rosa C, Srivastava T, et al. (2010) Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines. Vaccine 28: 1547-1557.
51. Anderson RJ, Schneider J, (2007) Plasmid DNA and viral vector-based vaccines for the treatment of cancer. Vaccine 25Suppl 2: B24-34.
52. Dunham SP, (2002) The application of nucleic acid vaccines in veterinary medicine. Res Vet Sci 73: 9-16.
53. Moore AC, Hill AV, (2004) Progress in DNA-based heterologous prime-boost immunization strategies for malaria. Immunol Rev 199: 126-143.
54. Kent SJ, Zhao A, Best SJ, Chandler JD, Boyle DB, et al. (1998) Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J Virol 72: 10180-10188.
55. Amara RR, Villinger F, Altman JD, Lydy SL, O'Neil SP, et al. (2001) Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292: 69-74.
56. Fournillier A, Gerossier E, Evlashev A, Schmitt D, Simon B, et al. (2007) An accelerated vaccine schedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses. Vaccine 25: 7339-7353.
57. Earl PL, Cotter C, Moss B, VanCott T, Currier J, et al. (2009) Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines. Vaccine 27: 5885-5895.
58. Kreijtz JH, Suezer Y, de Mutsert G, van den Brand JM, van Amerongen G, et al. (2009) Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses. Vaccine 27: 6296-6299.
59. Harrop R, Connolly N, Redchenko I, Valle J, Saunders M, et al. (2006) Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin Cancer Res 12: 3416-3424.
60. Ramirez JC, Gherardi MM, Rodriguez D, Esteban M, (2000) Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector. J Virol 74: 7651-7655.
61. Chiam R, Sharp E, Maan S, Rao S, Mertens P, et al. (2009) Induction of antibody responses to African horse sickness virus (AHSV) in ponies after vaccination with recombinant modified vaccinia Ankara (MVA). PLoS One 4: e5997.
62. Roy P, Urakawa T, Van Dijk AA, Erasmus BJ, (1990) Recombinant virus vaccine for bluetongue disease in sheep. J Virol 64: 1998-2003.
63. Ma G, Eschbaumer M, Said A, Hoffmann B, Beer M, et al. (2012) An equine herpesvirus type 1 (EHV-1) expressing VP2 and VP5 of serotype 8 bluetongue virus (BTV-8) induces protection in a murine infection model. PLoS One 7: e34425.
64. Wade-Evans AM, Woolhouse T, O'Hara R, Hamblin C, (1993) The use of African horse sickness virus VP7 antigen, synthesised in bacteria, and anti-VP7 monoclonal antibodies in a competitive ELISA. J Virol Methods 45: 179-188.